Citi Pharma Statistics
Total Valuation
Citi Pharma has a market cap or net worth of PKR 7.94 billion. The enterprise value is 7.67 billion.
Market Cap | 7.94B |
Enterprise Value | 7.67B |
Important Dates
The next estimated earnings date is Friday, October 4, 2024.
Earnings Date | Oct 4, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Citi Pharma has 228.46 million shares outstanding. The number of shares has decreased by -0.26% in one year.
Shares Outstanding | 228.46M |
Shares Change (YoY) | -0.26% |
Shares Change (QoQ) | +0.08% |
Owned by Insiders (%) | 52.00% |
Owned by Institutions (%) | 11.90% |
Float | 106.35M |
Valuation Ratios
The trailing PE ratio is 9.84 and the forward PE ratio is 9.15.
PE Ratio | 9.84 |
Forward PE | 9.15 |
PS Ratio | 0.61 |
PB Ratio | 1.45 |
P/FCF Ratio | 23.31 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 5.75, with an EV/FCF ratio of 22.51.
EV / Earnings | 9.51 |
EV / Sales | 0.59 |
EV / EBITDA | 5.75 |
EV / EBIT | 6.26 |
EV / FCF | 22.51 |
Financial Position
The company has a current ratio of 1.36, with a Debt / Equity ratio of 24.10.
Current Ratio | 1.36 |
Quick Ratio | 0.70 |
Debt / Equity | 24.10 |
Debt / EBITDA | 0.99 |
Debt / FCF | 3.88 |
Interest Coverage | 28.21 |
Financial Efficiency
Return on equity (ROE) is 15.06% and return on invested capital (ROIC) is 11.65%.
Return on Equity (ROE) | 15.06% |
Return on Assets (ROA) | 7.44% |
Return on Capital (ROIC) | 11.65% |
Revenue Per Employee | 22.01M |
Profits Per Employee | 1.36M |
Employee Count | 594 |
Asset Turnover | 1.27 |
Inventory Turnover | 3.90 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +71.25% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +71.25% |
50-Day Moving Average | 31.32 |
200-Day Moving Average | 26.88 |
Relative Strength Index (RSI) | 60.30 |
Average Volume (20 Days) | 2,887,341 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Citi Pharma had revenue of PKR 13.07 billion and earned 805.98 million in profits. Earnings per share was 3.53.
Revenue | 13.07B |
Gross Profit | 1.57B |
Operating Income | 1.22B |
Pretax Income | 1.30B |
Net Income | 805.98M |
EBITDA | 1.33B |
EBIT | 1.22B |
Earnings Per Share (EPS) | 3.53 |
Balance Sheet
The company has 1.60 billion in cash and 1.32 billion in debt, giving a net cash position of 275.32 million or 1.21 per share.
Cash & Cash Equivalents | 1.60B |
Total Debt | 1.32B |
Net Cash | 275.32M |
Net Cash Per Share | 1.21 |
Equity (Book Value) | 5.48B |
Book Value Per Share | 24.00 |
Working Capital | 1.79B |
Cash Flow
In the last 12 months, operating cash flow was 925.26 million and capital expenditures -584.65 million, giving a free cash flow of 340.61 million.
Operating Cash Flow | 925.26M |
Capital Expenditures | -584.65M |
Free Cash Flow | 340.61M |
FCF Per Share | 1.49 |
Margins
Gross margin is 12.05%, with operating and profit margins of 9.36% and 6.17%.
Gross Margin | 12.05% |
Operating Margin | 9.36% |
Pretax Margin | 9.98% |
Profit Margin | 6.17% |
EBITDA Margin | 10.17% |
EBIT Margin | 9.36% |
FCF Margin | 2.61% |
Dividends & Yields
This stock pays an annual dividend of 2.50, which amounts to a dividend yield of 7.30%.
Dividend Per Share | 2.50 |
Dividend Yield | 7.30% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | 2 |
Payout Ratio | 70.69% |
Buyback Yield | 0.26% |
Shareholder Yield | 7.56% |
Earnings Yield | 10.16% |
FCF Yield | 4.29% |
Stock Splits
The last stock split was on October 18, 2021. It was a forward split with a ratio of 1.1.
Last Split Date | Oct 18, 2021 |
Split Type | Forward |
Split Ratio | 1.1 |